News | May 14, 2025
Sai Life Sciences FY25 PAT higher by 105% to Rs. 170 Cr
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
Haloperidol Decanoate Injection indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy
The Protect VL project was born out of a vision to reduce the environmental footprint of medical devices
The company has posted net profit of Rs. 84.29 crores for the Financial Year ended March 31, 2025
The inspection conducted from December 16, 2024 to December 20, 2024 by the Brazil Health Regulatory Agency (ANVISA)
The company has posted net profit of Rs. 118.01 crores for the Financial Year ended March 31, 2025
Tolvaptan Tablets are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
This marks yet another milestone in our series of successful audits over the past year
The company has posted net profit of Rs. 338.55 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 1,767.63 crores for the Financial Year ended March 31, 2025
Subscribe To Our Newsletter & Stay Updated
